Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
ELOS's Cash-to-Debt is ranked higher than
96% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.54 vs. ELOS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
ELOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 65.7  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.74
ELOS's Equity-to-Asset is ranked higher than
67% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ELOS: 0.74 )
Ranked among companies with meaningful Equity-to-Asset only.
ELOS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.61  Med: 0.76 Max: 0.89
Current: 0.74
0.61
0.89
Piotroski F-Score: 5
Altman Z-Score: 4.81
Beneish M-Score: -2.67
WACC vs ROIC
8.21%
-2.03%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -0.11
ELOS's Operating Margin % is ranked lower than
57% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 3.45 vs. ELOS: -0.11 )
Ranked among companies with meaningful Operating Margin % only.
ELOS' s Operating Margin % Range Over the Past 10 Years
Min: -43.96  Med: -2.35 Max: 22
Current: -0.11
-43.96
22
Net Margin % -1.40
ELOS's Net Margin % is ranked lower than
57% of the 303 Companies
in the Global Medical Devices industry.

( Industry Median: 1.77 vs. ELOS: -1.40 )
Ranked among companies with meaningful Net Margin % only.
ELOS' s Net Margin % Range Over the Past 10 Years
Min: -43.1  Med: -1.27 Max: 22.16
Current: -1.4
-43.1
22.16
ROE % -2.01
ELOS's ROE % is ranked lower than
59% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.13 vs. ELOS: -2.01 )
Ranked among companies with meaningful ROE % only.
ELOS' s ROE % Range Over the Past 10 Years
Min: -19.9  Med: -1.43 Max: 14.7
Current: -2.01
-19.9
14.7
ROA % -1.50
ELOS's ROA % is ranked lower than
55% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: 0.49 vs. ELOS: -1.50 )
Ranked among companies with meaningful ROA % only.
ELOS' s ROA % Range Over the Past 10 Years
Min: -14.56  Med: -1.06 Max: 12.64
Current: -1.5
-14.56
12.64
ROC (Joel Greenblatt) % 1.00
ELOS's ROC (Joel Greenblatt) % is ranked lower than
55% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 6.15 vs. ELOS: 1.00 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
ELOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -397.3  Med: -14.81 Max: 133.88
Current: 1
-397.3
133.88
3-Year Revenue Growth Rate 6.30
ELOS's 3-Year Revenue Growth Rate is ranked higher than
54% of the 239 Companies
in the Global Medical Devices industry.

( Industry Median: 5.30 vs. ELOS: 6.30 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
ELOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.3 Max: 190.6
Current: 6.3
0
190.6
3-Year EBITDA Growth Rate 41.40
ELOS's 3-Year EBITDA Growth Rate is ranked higher than
86% of the 210 Companies
in the Global Medical Devices industry.

( Industry Median: 6.30 vs. ELOS: 41.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
ELOS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -46.2  Med: 14.95 Max: 99.5
Current: 41.4
-46.2
99.5
3-Year EPS without NRI Growth Rate -37.00
ELOS's 3-Year EPS without NRI Growth Rate is ranked lower than
86% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 2.90 vs. ELOS: -37.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
ELOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -64  Med: -18.8 Max: 98.2
Current: -37
-64
98.2
GuruFocus has detected 2 Warning Signs with Syneron Medical Ltd $ELOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» ELOS's 30-Y Financials

Financials (Next Earnings Date: 2017-11-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

ELOS Guru Trades in Q2 2016

Chuck Royce 788,159 sh (+10.52%)
Charles Brandes 2,723,535 sh (+8.53%)
Jim Simons 965,106 sh (+3.91%)
Mario Gabelli 24,000 sh (unchged)
» More
Q3 2016

ELOS Guru Trades in Q3 2016

Charles Brandes 3,414,913 sh (+25.39%)
Jim Simons 1,021,606 sh (+5.85%)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 420,659 sh (-46.63%)
» More
Q4 2016

ELOS Guru Trades in Q4 2016

Jim Simons 1,141,441 sh (+11.73%)
Charles Brandes 3,660,613 sh (+7.19%)
Mario Gabelli 24,000 sh (unchged)
Chuck Royce 69,200 sh (-83.55%)
» More
Q1 2017

ELOS Guru Trades in Q1 2017

Discovery Group I, LLC 1,221,310 sh (New)
Charles Brandes 3,680,764 sh (+0.55%)
Chuck Royce 69,200 sh (unchged)
Mario Gabelli 24,000 sh (unchged)
Jim Simons 1,104,580 sh (-3.23%)
» More
» Details

Insider Trades

Latest Guru Trades with ELOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices  
Compare:NAS:RWLK, XTAE:MDGS, AMEX:NSPR, XTAE:MZOR » details
Traded in other countries:FGD.Germany,
Headquarter Location:Israel
Syneron Medical Ltd designs, develops & markets aesthetic medical products based on its proprietary technologies. Its offers Skin Rejuvenation, Age Spots, Cellulite Reduction, Acne among others.

Syneron Medical Ltd., was incorporated in the State of Israel in July 2000. The Company completed its initial public offering of ordinary shares in August 2004. It designs, develops and markets aesthetic medical products based on its various technologies including its proprietary Electro-Optical Synergy, or ELOS, technology, which uses the synergy between electrical energy, including radiofrequency or RF energy, and optical energy to provide effective, safe and affordable aesthetic medical treatments. The Company's products, which it sells mainly to physicians and other practitioners, target non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin and laser-assisted lipolysis and topical skin brightening products.

Ratios

vs
industry
vs
history
PB Ratio 1.87
ELOS's PB Ratio is ranked higher than
71% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 2.92 vs. ELOS: 1.87 )
Ranked among companies with meaningful PB Ratio only.
ELOS' s PB Ratio Range Over the Past 10 Years
Min: 0.58  Med: 1.57 Max: 3.95
Current: 1.87
0.58
3.95
PS Ratio 1.30
ELOS's PS Ratio is ranked higher than
76% of the 290 Companies
in the Global Medical Devices industry.

( Industry Median: 3.32 vs. ELOS: 1.30 )
Ranked among companies with meaningful PS Ratio only.
ELOS' s PS Ratio Range Over the Past 10 Years
Min: 0.77  Med: 1.65 Max: 6.91
Current: 1.3
0.77
6.91
Price-to-Free-Cash-Flow 74.83
ELOS's Price-to-Free-Cash-Flow is ranked lower than
83% of the 110 Companies
in the Global Medical Devices industry.

( Industry Median: 32.13 vs. ELOS: 74.83 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
ELOS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 4.32  Med: 19.7 Max: 291.84
Current: 74.83
4.32
291.84
Price-to-Operating-Cash-Flow 43.31
ELOS's Price-to-Operating-Cash-Flow is ranked lower than
83% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 19.50 vs. ELOS: 43.31 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
ELOS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.16  Med: 19.4 Max: 637.06
Current: 43.31
4.16
637.06
EV-to-EBIT 503.98
ELOS's EV-to-EBIT is ranked lower than
99% of the 177 Companies
in the Global Medical Devices industry.

( Industry Median: 24.67 vs. ELOS: 503.98 )
Ranked among companies with meaningful EV-to-EBIT only.
ELOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -119.9  Med: -3.8 Max: 691.6
Current: 503.98
-119.9
691.6
EV-to-EBITDA 35.55
ELOS's EV-to-EBITDA is ranked lower than
81% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: 17.99 vs. ELOS: 35.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
ELOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -294.8  Med: 13.5 Max: 173.3
Current: 35.55
-294.8
173.3
Current Ratio 2.68
ELOS's Current Ratio is ranked higher than
52% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.64 vs. ELOS: 2.68 )
Ranked among companies with meaningful Current Ratio only.
ELOS' s Current Ratio Range Over the Past 10 Years
Min: 2.59  Med: 3.65 Max: 10.72
Current: 2.68
2.59
10.72
Quick Ratio 1.84
ELOS's Quick Ratio is ranked lower than
53% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. ELOS: 1.84 )
Ranked among companies with meaningful Quick Ratio only.
ELOS' s Quick Ratio Range Over the Past 10 Years
Min: 1.84  Med: 3.37 Max: 10.39
Current: 1.84
1.84
10.39
Days Inventory 127.64
ELOS's Days Inventory is ranked higher than
51% of the 285 Companies
in the Global Medical Devices industry.

( Industry Median: 128.08 vs. ELOS: 127.64 )
Ranked among companies with meaningful Days Inventory only.
ELOS' s Days Inventory Range Over the Past 10 Years
Min: 57.94  Med: 110.49 Max: 205.18
Current: 127.64
57.94
205.18
Days Sales Outstanding 67.88
ELOS's Days Sales Outstanding is ranked higher than
51% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 68.17 vs. ELOS: 67.88 )
Ranked among companies with meaningful Days Sales Outstanding only.
ELOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 67.88  Med: 78.41 Max: 117.09
Current: 67.88
67.88
117.09
Days Payable 57.67
ELOS's Days Payable is ranked higher than
52% of the 258 Companies
in the Global Medical Devices industry.

( Industry Median: 54.45 vs. ELOS: 57.67 )
Ranked among companies with meaningful Days Payable only.
ELOS' s Days Payable Range Over the Past 10 Years
Min: 50.87  Med: 66.08 Max: 106.72
Current: 57.67
50.87
106.72

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio 1.80
ELOS's 3-Year Average Share Buyback Ratio is ranked higher than
94% of the 226 Companies
in the Global Medical Devices industry.

( Industry Median: -4.10 vs. ELOS: 1.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ELOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -70.6  Med: -6.85 Max: 1.8
Current: 1.8
-70.6
1.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 3.62
ELOS's Price-to-Net-Current-Asset-Value is ranked higher than
73% of the 204 Companies
in the Global Medical Devices industry.

( Industry Median: 6.83 vs. ELOS: 3.62 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
ELOS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.86  Med: 2.79 Max: 7.94
Current: 3.62
0.86
7.94
Price-to-Tangible-Book 2.14
ELOS's Price-to-Tangible-Book is ranked higher than
75% of the 256 Companies
in the Global Medical Devices industry.

( Industry Median: 3.98 vs. ELOS: 2.14 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
ELOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.71  Med: 2.04 Max: 7.72
Current: 2.14
0.71
7.72
Price-to-Intrinsic-Value-Projected-FCF 9.02
ELOS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
88% of the 141 Companies
in the Global Medical Devices industry.

( Industry Median: 2.41 vs. ELOS: 9.02 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
ELOS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.46  Med: 1.7 Max: 45.56
Current: 9.02
0.46
45.56
Price-to-Median-PS-Value 0.79
ELOS's Price-to-Median-PS-Value is ranked higher than
73% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. ELOS: 0.79 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
ELOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.52  Med: 1.21 Max: 8.39
Current: 0.79
0.52
8.39
Earnings Yield (Greenblatt) % 0.20
ELOS's Earnings Yield (Greenblatt) % is ranked lower than
54% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 1.25 vs. ELOS: 0.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
ELOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -343.9  Med: -1.6 Max: 6887.2
Current: 0.2
-343.9
6887.2

More Statistics

Revenue (TTM) (Mil) $296.29
EPS (TTM) $ -0.11
Beta1.03
Short Percentage of Float1.44%
52-Week Range $6.18 - 11.43
Shares Outstanding (Mil)35.23

Analyst Estimate

Dec17
Revenue (Mil $)
EPS ($) 0.43
EPS without NRI ($) 0.43
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for ELOS

Headlines

Articles On GuruFocus.com
Syneron Candela Completes Previously Announced Transaction with Funds Advised by Apax Partners and B Jul 17 2017 
Syneron Candela Announces Shareholder Approval of Proposed Acquisition by Funds Advised by Apax Part Jun 15 2017 
Syneron Candela Announces End of Go-Shop Period May 10 2017 
Syneron Candela Announces Agreement to be Acquired by Funds advised by Apax Partners for $11.00/shar Apr 03 2017 
Retrophin At All-Time High Levels on RE-024 FDA-Status; Syneron Settles Legal Battle Jun 05 2015 
Why Is Seth Klarman Loading Up on Syneron Medical? Aug 29 2011 
Seth Klarman’s Baupost Group Buys Microsoft Corp., BP, Allied Nevada Gold, Sells Audiovox Corp. Aug 12 2011 
Seth Klarman More Than Doubles Holdings in Syneron Medical Jul 12 2011 
Top Seth Klarman Holding, ELOS Rockets Up 20% Feb 16 2011 
Baupost’s Seth Klarman Buys Enzon Inc., Viasat Inc., Sells Horizon Lines Inc., News Corp., PDL Bio Nov 12 2009 

More From Other Websites
Syneron Candela Completes Previously Announced Transaction with Funds Advised by Apax Partners and... Jul 17 2017
ETFs with exposure to Syneron Medical Ltd. : July 10, 2017 Jul 10 2017
Syneron Medical Ltd. breached its 50 day moving average in a Bearish Manner : ELOS-US : July 7, 2017 Jul 07 2017
Waiting For Bigger Bids? Jun 22 2017
Syneron Medical Ltd. breached its 50 day moving average in a Bearish Manner : ELOS-US : June 21,... Jun 21 2017
ETFs with exposure to Syneron Medical Ltd. : June 19, 2017 Jun 19 2017
Syneron Medical Ltd. :ELOS-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Syneron Candela Announces Shareholder Approval of Proposed Acquisition by Funds Advised by Apax... Jun 15 2017
Featured Company News - Zimmer Biomet's China Manufacturing Unit Gets US FDA Nod After Addressing... Jun 15 2017
Syneron Medical Ltd. breached its 50 day moving average in a Bearish Manner : ELOS-US : May 29, 2017 May 29 2017
Syneron Medical Ltd. – Value Analysis (NASDAQ:ELOS) : May 18, 2017 May 18 2017
Syneron Medical reports 1Q loss May 17 2017
Syneron Medical Reports First Quarter 2017 Revenue of $66.9 Million May 17 2017
Syneron Candela Announces End of Go-Shop Period May 10 2017
Apax to buy Israeli aesthetic device firm Syneron for $397 mln Apr 03 2017
Syneron Candela Announces Agreement to be Acquired by Funds advised by Apax Partners for... Apr 03 2017
Apax close to $500 mln deal to buy Israel's Syneron - reports Apr 02 2017
Syneron Candela Announces CE Mark for CO2RE® Intima Mar 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}